Apollo Endosurgery - APEN Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APEN shares.
View APEN analyst ratings or view top-rated stocks.

3 analysts have issued 1 year price objectives for Apollo Endosurgery's stock. Their APEN share price forecasts range from $10.00 to $13.00. On average, they expect the company's share price to reach $11.25 in the next year. This suggests a possible upside of 12.3% from the stock's current price.
View analysts price targets for APEN or view top-rated stocks among Wall Street analysts.

Apollo Endosurgery's stock was trading at $8.43 at the start of the year. Since then, APEN shares have increased by 18.9% and is now trading at $10.02.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our APEN earnings forecast.

Apollo Endosurgery, Inc. (NASDAQ:APEN) announced its quarterly earnings results on Sunday, October, 31st. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. The biotechnology company had revenue of $16.35 million for the quarter, compared to the consensus estimate of $16.20 million. Apollo Endosurgery had a negative net margin of 56.74% and a negative trailing twelve-month return on equity of 78.73%. During the same period last year, the business posted ($0.11) EPS.

Apollo Endosurgery issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $75.00 million-$76.00 million, compared to the consensus revenue estimate of $73.95 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Apollo Endosurgery's stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (6.80%), Gagnon Securities LLC (4.29%), Vanguard Group Inc. (3.27%), Silverarc Capital Management LLC (2.79%), Russell Investments Group Ltd. (2.34%) and Parkman Healthcare Partners LLC (1.58%). Insiders that own company stock include Chas Mckhann, Cpmg Inc, David Pacitti, Jeffrey G Black, John R Barr, Neil Gagnon and R Kent Mcgaughy Jr.
View institutional ownership trends.

Shares of APEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APEN stock can currently be purchased for approximately $10.02.

Apollo Endosurgery (NASDAQ:APEN) has a market capitalization of $417.13 million and generates $62.99 million in revenue each year. The biotechnology company earns $-24,680,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

The company employs 202 workers across the globe.

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The official website for the company is www.apolloendo.com. The biotechnology company can be reached via phone at (512) 279-5100, via email at investor-relations@apolloendo.com, or via fax at 858-678-0900.